norfloxacin has been researched along with Ascites in 25 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 9.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 7.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 7.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 5.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Selective intestinal decontamination (SID) for 7 days with norfloxacin (NF) was performed in 15 patients with schistosomal hepatic fibrosis (SHF) and low-protein ascites." | 5.07 | Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and low-protein ascites. ( Abou Seif Helmy, M; el Aggan, HA; el-Aggan, HA; Guirguis, TG, 1993) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 3.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| " The bactDNA translocation was investigated in 226 patients with cirrhosis and noninfected ascites, 22 patients with spontaneous bacterial peritonitis, and 10 patients with ascites receiving continuous norfloxacin." | 3.74 | Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. ( Bellot, P; Caño, R; Francés, R; González-Navajas, JM; Moreu, R; Muñoz, C; Pascual, S; Pérez-Mateo, M; Such, J; Zapater, P, 2008) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 3.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "This study analyzes hospital acquired bacterial infections in cirrhotic patients with ascites and low levels of total protein in ascitic fluid (n = 53) and cirrhotic patients with gastrointestinal hemorrhage (n = 26), both submitted to selective intestinal decontamination with norfloxacin during the hospitalization." | 1.28 | [An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination]. ( Balanzó, J; Fábrega, E; Guarner, C; Méndez, C; Soriano, G; Such, J; Teixidó, M; Tena, F; Tomás, A; Villanueva, C, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (36.00) | 18.2507 |
| 2000's | 9 (36.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yim, HJ | 1 |
| Suh, SJ | 1 |
| Jung, YK | 1 |
| Yim, SY | 1 |
| Seo, YS | 1 |
| Lee, YR | 1 |
| Park, SY | 1 |
| Jang, JY | 1 |
| Kim, YS | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Um, SH | 1 |
| Moreau, R | 1 |
| Elkrief, L | 1 |
| Bureau, C | 1 |
| Perarnau, JM | 1 |
| Thévenot, T | 1 |
| Saliba, F | 1 |
| Louvet, A | 1 |
| Nahon, P | 1 |
| Lannes, A | 1 |
| Anty, R | 1 |
| Hillaire, S | 1 |
| Pasquet, B | 1 |
| Ozenne, V | 1 |
| Rudler, M | 1 |
| Ollivier-Hourmand, I | 1 |
| Robic, MA | 1 |
| d'Alteroche, L | 1 |
| Di Martino, V | 1 |
| Ripault, MP | 1 |
| Pauwels, A | 2 |
| Grangé, JD | 2 |
| Carbonell, N | 1 |
| Bronowicki, JP | 1 |
| Payancé, A | 1 |
| Rautou, PE | 1 |
| Valla, D | 1 |
| Gault, N | 1 |
| Lebrec, D | 1 |
| Saffouri, GB | 1 |
| Wittich, CM | 1 |
| Mostafa, T | 1 |
| Badra, G | 1 |
| Abdallah, M | 1 |
| Salerno, F | 1 |
| La Mura, V | 1 |
| Elfert, A | 1 |
| Abo Ali, L | 1 |
| Soliman, S | 1 |
| Ibrahim, S | 1 |
| Abd-Elsalam, S | 1 |
| Corradi, F | 1 |
| Brusasco, C | 1 |
| Fernández, J | 1 |
| Vila, J | 1 |
| Ramirez, MJ | 1 |
| Seva-Pereira, T | 1 |
| Fernández-Varo, G | 1 |
| Mosbah, IB | 1 |
| Acevedo, J | 1 |
| Silva, A | 1 |
| Rocco, PR | 1 |
| Pelosi, P | 1 |
| Gines, P | 1 |
| Navasa, M | 1 |
| Albillos, A | 2 |
| de la Hera, A | 1 |
| González, M | 1 |
| Moya, JL | 1 |
| Calleja, JL | 1 |
| Monserrat, J | 2 |
| Ruiz-del-Arbol, L | 1 |
| Alvarez-Mon, M | 2 |
| Hera Ad, Ade L | 1 |
| Reyes, E | 1 |
| Muñoz, L | 1 |
| Nieto, M | 1 |
| Prieto, A | 1 |
| Sanz, E | 1 |
| Sandhu, BS | 1 |
| Gupta, R | 1 |
| Sharma, J | 1 |
| Singh, J | 1 |
| Murthy, NS | 1 |
| Sarin, SK | 1 |
| Romney, R | 1 |
| Mathurin, P | 1 |
| Ganne-Carrié, N | 1 |
| Halimi, C | 1 |
| Medini, A | 1 |
| Lemaitre, P | 1 |
| Gruaud, P | 1 |
| Jouannaud, V | 1 |
| Delacour, T | 1 |
| Boudjema, H | 1 |
| Chaput, JC | 1 |
| Cadranel, JF | 1 |
| Itha, S | 1 |
| Sharma, A | 1 |
| Bhatt, G | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Francés, R | 2 |
| González-Navajas, JM | 2 |
| Zapater, P | 2 |
| Muñoz, C | 2 |
| Caño, R | 2 |
| Pascual, S | 2 |
| Márquez, D | 1 |
| Santana, F | 1 |
| Pérez-Mateo, M | 2 |
| Such, J | 3 |
| Moreu, R | 1 |
| Bellot, P | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Salazar, L | 1 |
| Aller Fuente, R | 1 |
| del Olmo Martínez, L | 1 |
| de la Calle Valverde, F | 1 |
| Arranz Santos, T | 1 |
| González Hernández, JM | 1 |
| Schölmerich, J | 2 |
| Gerbes, AL | 1 |
| Andus, T | 1 |
| Leser, HG | 1 |
| Dupeyron, C | 1 |
| Mangeney, N | 1 |
| Sedrati, L | 1 |
| Campillo, B | 1 |
| Fouet, P | 1 |
| Leluan, G | 1 |
| Wesenfelder, L | 1 |
| Eugène, C | 1 |
| el Aggan, HA | 1 |
| el-Aggan, HA | 1 |
| Abou Seif Helmy, M | 1 |
| Guirguis, TG | 1 |
| Novella, M | 1 |
| Solà, R | 1 |
| Soriano, G | 2 |
| Andreu, M | 1 |
| Gana, J | 1 |
| Ortiz, J | 1 |
| Coll, S | 1 |
| Sàbat, M | 1 |
| Vila, MC | 1 |
| Guarner, C | 2 |
| Vilardell, F | 1 |
| Glück, T | 1 |
| Roulot, D | 1 |
| Pelletier, G | 1 |
| Pariente, EA | 1 |
| Denis, J | 1 |
| Ink, O | 1 |
| Blanc, P | 1 |
| Richardet, JP | 1 |
| Vinel, JP | 1 |
| Delisle, F | 1 |
| Fischer, D | 1 |
| Flahault, A | 1 |
| Amiot, X | 1 |
| Jeffries, MA | 1 |
| Stern, MA | 1 |
| Gunaratnam, NT | 1 |
| Fontana, RJ | 1 |
| Tomás, A | 1 |
| Teixidó, M | 1 |
| Méndez, C | 1 |
| Tena, F | 1 |
| Fábrega, E | 1 |
| Villanueva, C | 1 |
| Balanzó, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Trial Assessing Norfloxacin in the Prevention of Complications in Patients With Cirrhosis and Severe Liver Failure[NCT01037959] | Phase 3 | 291 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to lack of recruitement) | ||
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy[NCT05786859] | Early Phase 1 | 124 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations[NCT02799160] | 22 participants (Actual) | Observational | 2016-10-01 | Active, not recruiting | |||
| A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.[NCT06158152] | 48 participants (Anticipated) | Interventional | 2024-01-20 | Not yet recruiting | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for norfloxacin and Ascites
| Article | Year |
|---|---|
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites].
Topics: Anti-Bacterial Agents; Ascites; Bacteria; Bacterial Infections; Blood; Endoscopy; Humans; Leukocyte | 1995 |
[Spontaneous bacterial peritonitis].
Topics: Animals; Ascites; Bacterial Infections; Bacterial Translocation; Cefotaxime; Diagnosis, Differential | 1998 |
9 trials available for norfloxacin and Ascites
| Article | Year |
|---|---|
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Topics: Adult; Anti-Bacterial Agents; Ascites; Bacterial Infections; Female; Humans; Interleukin-10; Interle | 2015 |
Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Bacterial Infections; Cause of Death; Egypt; | 2016 |
Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Ascites; Carrier Proteins; Case-Control Studies; Entero | 2004 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Adult; Analysis of Variance; Anti-Infective Agents; Ascites; Chi-Square Distribution; Cisapride; Dru | 2005 |
Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and low-protein ascites.
Topics: Adult; Animals; Ascites; Ascitic Fluid; Humans; Intestines; Liver Cirrhosis; Norfloxacin; Peritoniti | 1993 |
Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Drug Administration Schedule; Drug Resistance, | 1997 |
Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.
Topics: Adult; Aged; Anti-Infective Agents; Ascites; Double-Blind Method; Feces; Female; France; Gram-Negati | 1998 |
13 other studies available for norfloxacin and Ascites
| Article | Year |
|---|---|
83-year-old man with abdominal swelling and lower extremity edema.
Topics: Abdominal Cavity; Aged, 80 and over; Anti-Infective Agents; Ascites; Cefotaxime; Diagnosis, Differen | 2013 |
Treatment of Spontaneous Bacterial Peritonitis.
Topics: Age Factors; Albumins; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ascites; Bilirubin; Drug Resis | 2015 |
Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Translocatio | 2012 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Results of a multicenter prospective study.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Asci | 2005 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Cisapride; Drug Therapy, Combination; Gastroin | 2006 |
Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; | 2007 |
Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; DNA, Bacterial; Female; Humans; I | 2008 |
[Spontaneous bacterial peritonitis due to Gemella morbillorum in a patient under chronic treatment with norfloxacin].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Humans; Liver Cirrhosis, Alcoholic; Mal | 2008 |
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.
Topics: Ascites; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Human | 1994 |
[Peritoneal tuberculosis masked by fluoroquinolones in a patient with liver cirrhosis].
Topics: Anti-Bacterial Agents; Ascites; Drug Therapy, Combination; Humans; Liver Cirrhosis, Alcoholic; Male; | 1993 |
Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Ascitic Fluid; | 1999 |
[An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination].
Topics: Ascites; Bacterial Infections; Cross Infection; Decontamination; Female; Humans; Incidence; Intestin | 1991 |